exome sequencing
GeneDx Launches Program to Boost Access to Exome Testing for Pediatric Epilepsy Patients
In partnership with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, the program will also contribute to GeneDx's rare disease database.
GeneDx Stock Soars as Firm Reports 44 Percent Revenue Growth, $1.2M Adjusted Net Income in Q3
Premium
Revenues in the third quarter were driven by diagnostic exome and genome tests, which grew 76 percent in revenue and 46 percent in volume, prompting the firm to raise its 2024 guidance.
GeneDx Q2 Revenues Grow 45 Percent Driven by Exome, Genome Tests
The company saw a 52 percent year-over-year increase in whole-exome and whole-genome testing volume during Q2, booking $50.7 million in revenues for this business segment.
Craig-Hallum Initiates Coverage of GeneDx With Buy Rating
The investment bank cited the firm's strong growth in its whole-exome and whole-genome sequencing businesses and a clear path to profitability.
German Precision Medicine Model Project Gets Ready for Kickoff as Commercial Providers Cry Foul
The €700 million project will pilot diagnostic genomic testing for cancer and rare diseases for at least five years, but private labs cannot participate.